TP53 and acute myeloid leukemia: Clonal evolution analysis showed that out of all the clones identified in this patient, exclusively this mutant TP53 clone expanded significantly over time, from about 9% at pre-BMT, to about 42% at post-BMT and to almost 70% of the cell population when AML relapsed (Fig. 1C).